Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 100 entries
View as:

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04090736 Org: User:
Start: 09/24/19 End: 06/30/25 Due: 06/30/26

GEM05 for Patients With Multiple Myeloma Under 65 Years

Phase: N/A Priority: Normal
NCT ID: NCT00461747 Org: User:
Start: 03/31/06 End: 12/31/08 Due: 12/31/09

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03023527 Org: User:
Start: 01/31/17 End: 01/31/18 Due: 01/31/19

LAL-BR/2001: Study Treatment to Low Risk ALL

Phase: N/A Priority: Normal
NCT ID: NCT00526175 Org: User:
Start: 06/30/01 End: 12/31/15 Due: 12/31/16

VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years

Phase: N/A Priority: Normal
NCT ID: NCT02606825 Org: User:
Start: 07/31/15 End: 02/15/18 Due: 02/15/19

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03571997 Org: User:
Start: 06/15/18 End: 12/30/22 Due: 12/30/23

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02776605 Org: User:
Start: 06/30/16 End: 08/31/23 Due: 08/31/24

Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00388531 Org: User:
Start: 03/31/06 End: 06/30/11 Due: 06/30/12

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT04687761 Org: User:
Start: 11/04/20 End: 11/30/24 Due: 11/30/25

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Phase: N/A Priority: Normal
NCT ID: NCT00480363 Org: User:
Start: 05/31/07 End: 07/31/13 Due: 07/31/14

Treatment of Acute Myeloblastic Leukemia in Younger Patients

Phase: N/A Priority: Normal
NCT ID: NCT00390715 Org: User:
Start: 01/31/99 End: 01/31/10 Due: 01/31/11

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06544785 Org: User:
Start: 09/02/24 End: 05/31/32 Due: 05/31/33

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Phase: N/A Priority: Normal
NCT ID: NCT01237249 Org: User:
Start: 02/28/11 End: 05/31/16 Due: 05/31/17

Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00652041 Org: User:
Start: 01/31/07 End: 06/30/10 Due: 06/30/11

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06574126 Org: User:
Start: 09/30/24 End: 09/30/32 Due: 09/30/33

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04178798 Org: User:
Start: 12/09/19 End: 12/03/24 Due: 12/03/25

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Phase: N/A Priority: Normal
NCT ID: NCT00662948 Org: User:
Start: 12/31/08 End: 10/30/17 Due: 10/30/18

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00853008 Org: User:
Start: 01/31/03 End: 12/31/12 Due: 12/31/13

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT01916252 Org: User:
Start: 09/30/13 End: 11/16/16 Due: 11/16/17

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00495547 Org: User:
Start: 02/28/09 End: 06/30/11 Due: 06/30/12

VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00391157 Org: User:
Start: 08/31/05 End: 01/31/08 Due: 01/31/09

Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04230239 Org: User:
Start: 12/26/19 End: 08/11/21 Due: 08/11/22

PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00944008 Org: User:
Start: 09/30/09 End: 07/31/12 Due: 07/31/13

Pethema Multiple Myeloma 2000

Phase: N/A Priority: Normal
NCT ID: NCT00560053 Org: User:
Start: 01/31/00 End: 02/28/05 Due: 02/28/06

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05849610 Org: User:
Start: 09/21/23 End: 07/31/29 Due: 07/31/30